Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research202

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research202

FiltersClear all

Status

Recruiting57
Not yet recruiting3
Enrolling by invitation3
Active, not recruiting56
Completed65
Terminated18

Study type

Interventional176
Observational26

Phase

Not applicable71
Phase 353
Phase 239
Not reported26
Phase 14
Phase 44

Investigator

Hani Lamie Ashamalla7
Alexander Ja-Ho Chou6
Dana Jeremy Lukin6
Daniel W Skupski4
Evelyn Cantillo4

Show all 50Show fewer

Department

Medicine103
Obstetrics and Gynecology17
Pediatrics16
Neurology12
Radiation Oncology9

Show all 19Show fewer

Condition

Prostatic Neoplasms10
Heart Failure8
Colitis, Ulcerative7
Breast Neoplasms6
COVID-196

Show all 50Show fewer

Intervention type

Other202
Drug807
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

Industry64
Other academic51
WCM (investigator-initiated)51
NIH22
Cooperative group14

Start date

Has results posted40

Other×Clear all

Showing 1–20 of 202 studiesSort:

Active, not recruitingInterventional · Phase 3NCT02193282 ↗
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Ashish SaxenaPI
Intervention
Other: Clinical Observation · Drug: Erlotinib Hydrochloride · Other: Laboratory Biomarker Analysis · Other: Placebo Administration
Dates
Feb 2015 – Dec 2025

FiltersClear all

Status

Recruiting57
Not yet recruiting3
Enrolling by invitation3
Active, not recruiting56
Completed65
Terminated18

Study type

Interventional176
Observational26

Phase

Not applicable71
Phase 353
Phase 239
Not reported26
Phase 14
Phase 44

Investigator

Hani Lamie Ashamalla7
Alexander Ja-Ho Chou6
Dana Jeremy Lukin6
Daniel W Skupski4
Evelyn Cantillo4

Show all 50Show fewer

Department

Medicine103
Obstetrics and Gynecology17
Pediatrics16
Neurology12
Radiation Oncology9

Show all 19Show fewer

Condition

Prostatic Neoplasms10
Heart Failure8
Colitis, Ulcerative7
Breast Neoplasms6
COVID-196

Show all 50Show fewer

Intervention type

Other202
Drug807
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

Industry64
Other academic51
WCM (investigator-initiated)51
NIH22
Cooperative group14

Start date

Has results posted40

Other×Clear all

Showing 1–20 of 202 studiesSort:

Active, not recruitingInterventional · Phase 3NCT02193282 ↗
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Ashish SaxenaPI
Intervention
Other: Clinical Observation · Drug: Erlotinib Hydrochloride · Other: Laboratory Biomarker Analysis · Other: Placebo Administration
Dates
Feb 2015 – Dec 2025

Phase 1/2

Phase 2/32

Manish A Shah4
Robert J. Kaner4
Scott T. Tagawa4
Ana M. Molina3
Catherine Butkus Small3
Cora Sternberg3
Eleni Andreopoulou3
Grant Ellsworth3
Harini Sarva3
Jia Ruan3
Louis J Aronne3
Mehraneh Dorna Jafari3
Michael Satlin3
Parag Goyal3
Ashish Saxena2
Anais Rameau2
Bernhard Kuhn2
Cheguevara Afaneh2
Erica Phillips2
Georgiana Alina Dobri2
Gioia Turitto2
Howard Alan Fine2
Holly G Prigerson2
Heather Lipkind2
Jeremy Adam Weingarten2
Melissa Frey2
Neel Mehta2
Randy Longman2
Robert S. Brown2
Shari Lipner2
Shoshana Rosenberg2
Sonja Blum2
Sonal Kumar2
Veerawat Phongtankuel2
Tony Rosen1
Allyson J Ocean1
Anna Podolanczuk1
Alexander Drelick1
Andrew F. Alexis1
Alexandra Gomez Arteaga1
Aliza B Solomon1
Aileen Gariepy1
Anthony O. Ahmed1
Alpana P. Shukla1
Bassem M Masri1

Surgery6

Emergency Medicine5

Neurological Surgery5

Otolaryngology Head and Neck Surgery3

Population Health Sciences3

Urology3

Cardiothoracic Surgery2

Rehabilitation Medicine2

Orthopaedic Surgery1

Pharmacology1

Crohn Disease6
Obesity6
Carcinoma, Non-Small-Cell Lung4
Carcinoma, Renal Cell4
Hypertension4
Inflammatory Bowel Diseases4
Lung Neoplasms4
Overweight4
Parkinson Disease4
Anxiety Disorders3
Atrial Fibrillation3
Breast Carcinoma In Situ3
Diabetes Mellitus, Type 23
Hodgkin Disease3
Liver Diseases3
Lung Diseases, Interstitial3
Metabolic Diseases3
Neoplasms3
Nutrition Disorders3
Pain3
Papillomavirus Infections3
Acquired Immunodeficiency Syndrome2
Acute Coronary Syndrome2
Alzheimer Disease2
Brain Neoplasms2
Burkitt Lymphoma2
Carcinosarcoma2
Caregiver Burden2
Chronic Pain2
Cognitive Dysfunction2
Colorectal Neoplasms2
Coronavirus Infections2
Dementia2
Depression2
Depression, Postpartum2
Endocrine System Diseases2
Escherichia coli Infections2
Glioblastoma2
Hematologic Neoplasms2
Leukemia, Biphenotypic, Acute2
Leukemia, Myeloid, Acute2
Pancreatic Neoplasms2
Patient Participation2
Respiratory Distress Syndrome2
Sepsis2

Radiation

Diagnostic test31

Dietary supplement14

Combination product11

Genetic7

Sponsor

Alliance for Clinical Trials in Oncology

Lung Non-Squamous Non-Small Cell CarcinomaStage IB Lung Non-Small Cell Carcinoma AJCC v7Stage II Lung Non-Small Cell Cancer AJCC v7+3 more

Active, not recruitingInterventional · Phase 3NCT02954874 ↗

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Eleni AndreopoulouPI

Intervention: Procedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy
Dates: Jan 2017 – Aug 2026
Sponsor: Southwest Oncology Group

Breast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more

Active, not recruitingInterventional · Phase 2NCT03092856 ↗

Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma

Ana M. MolinaPI

Intervention: Biological: Anti-OX40 Antibody PF-04518600 · Drug: Axitinib · Other: Laboratory Biomarker Analysis · Other: Placebo
Dates: Jul 2017 – Dec 2026 (est.)
Sponsor: USC Keck School of Medicine Norris Cancer Center

Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerRecurrent Renal Cell Carcinoma+1 more

Active, not recruitingInterventional · Phase 4NCT03315910 ↗

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Bradley B PuaPI

Intervention: Behavioral: Motivational Interviewing (MI) · Drug: Nicotine Replacement Therapy (NRT) · Drug: Nicotine Lozenge · Behavioral: Message Framing · Other: saliva sample
Dates: Oct 2017 – Oct 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Smoking Cessation

Active, not recruitingInterventional · Phase 2NCT03371719 ↗

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)

Hani Lamie AshamallaPI

Intervention: Drug: Apalutamide · Radiation: External Beam Radiation Therapy · Other: Placebo Administration
Dates: Jun 2018 – Mar 2025· Results posted
Sponsor: NRG Oncology

Recurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7

Active, not recruitingInterventional · Not applicableNCT03487185 ↗

A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

Daniel W SkupskiPI

Intervention: Device: Continuous Positive Airway Pressure · Other: Sleep Advice Control
Dates: Aug 2018 – Oct 2026 (est.)
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Develop

Obstructive Sleep Apnea of AdultPreeclampsiaObstetrical Complications

Active, not recruitingInterventional · Phase 3NCT03488693 ↗

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Hani Lamie AshamallaPI

Intervention: Radiation: Radiation · Other: No Radiation
Dates: Oct 2018 – Sep 2027 (est.)
Sponsor: Canadian Cancer Trials Group

Breast Cancer

Active, not recruitingInterventional · Not applicableNCT03499236 ↗

RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure

Maria KarasPI

Intervention: Device: V-Wave Interatrial Shunt · Other: Control
Dates: Sep 2018 – Oct 2023
Sponsor: V-Wave Ltd.

Heart Failure

Active, not recruitingInterventional · Phase 3NCT03533582 ↗

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Alexander Ja-Ho ChouPI

Intervention: Procedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Drug: Doxorubicin · Drug: Etoposide · Drug: Fluorouracil · Drug: Gemcitabine · Drug: Irinotecan · Drug: Oxaliplatin · Other: Patient Observation · Procedure: Resection · Drug: Sorafenib · Drug: Vincristine Sulfate
Dates: May 2018 – Mar 2027 (est.)
Sponsor: Children's Oncology Group

Childhood Hepatocellular CarcinomaChildhood Malignant Liver NeoplasmFibrolamellar Carcinoma+2 more

RecruitingInterventional · Phase 3NCT03678025 ↗

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Douglas S ScherrPI

Intervention: Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin
Dates: Sep 2018 – Apr 2033 (est.)
Sponsor: Southwest Oncology Group

Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

Active, not recruitingInterventional · Phase 2NCT03712202 ↗

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Jia RuanPI

Intervention: Drug: Bleomycin · Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine
Dates: Nov 2018 – Nov 2024· Results posted
Sponsor: City of Hope National Medical Center

Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma+11 more

Active, not recruitingInterventional · Phase 3NCT03737981 ↗

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: Ibrutinib · Biological: Obinutuzumab · Other: Observation Activity · Drug: Venetoclax
Dates: Jan 2019 – Jan 2025· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Active, not recruitingInterventional · Not applicableNCT03754114 ↗

Brain Oxygen Optimization in Severe TBI (BOOST3): A Comparative Effectiveness Study to Test the Efficacy of a Prescribed Treatment Protocol Based on Monitoring the Partial Pressure of Brain Tissue Oxygen.

Margaret HuynhPI

Intervention: Other: ICP + PbtO2 guided management strategy · Other: ICP guided management strategy
Dates: Aug 2019 – Nov 2027 (est.)
Sponsor: National Institute of Neurological Disorders & Stroke

Brain Injuries, Traumatic

Active, not recruitingInterventional · Phase 3NCT03793166 ↗

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Ana M. MolinaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib · Procedure: Computed Tomography · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Jun 2019 – Mar 2028 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Clear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more

Active, not recruitingInterventional · Phase 3NCT03803553 ↗

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Manish A ShahPI

Intervention: Drug: FOLFIRI Protocol · Other: ACTIVE SURVEILLANCE · Drug: Nivolumab Protocol · Drug: Encorafenib/Binimetinib/Cetuximab Protocol · Drug: Trastuzumab + Pertuzumab
Dates: Apr 2020 – Dec 2026 (est.)
Sponsor: The General Hospital Corporation (dba Massachusetts General Hospital)

Metastatic Colon CancerStage III Colon Cancer

Active, not recruitingInterventional · Phase 3NCT03811015 ↗

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Hani Lamie AshamallaPI

Intervention: Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Other: Fludeoxyglucose F-18 · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Other: Patient Observation · Procedure: Positron Emission Tomography
Dates: Aug 2019 – Jan 2030 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Active, not recruitingInterventional · Phase 2NCT03817398 ↗

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Alexander Ja-Ho ChouPI

Intervention: Procedure: Biospecimen Collection · Other: Drug Withdrawn · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Tyrosine Kinase Inhibitor
Dates: Nov 2019 – Sep 2026 (est.)
Sponsor: Children's Oncology Group

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Active, not recruitingInterventional · Phase 3NCT03833154 ↗

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation

Silvia Chiara FormentiPI

Intervention: Drug: Durvalumab · Other: Placebo · Drug: (Osimertinib cohort, single-arm, open-label separate cohort)
Dates: Mar 2019 – Oct 2028 (est.)
Sponsor: AstraZeneca, PLC

Carcinoma, Non-Small-Cell Lung

Active, not recruitingInterventional · Phase 3NCT03907488 ↗

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Jia RuanPI

Intervention: Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Biological: Filgrastim · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Vinblastine Sulfate
Dates: Aug 2019 – Mar 2024· Results posted
Sponsor: Southwest Oncology Group

Ann Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma+7 more

Active, not recruitingInterventional · Phase 3NCT03914612 ↗

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Evelyn CantilloPI

Intervention: Drug: Carboplatin · Procedure: Computed Tomography · Drug: Paclitaxel · Biological: Pembrolizumab · Other: Placebo Administration · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Aug 2019 – Dec 2022· Results posted
Sponsor: NRG Oncology

Endometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid Adenocarcinoma+13 more

‹ Prev1 2 3 4 5…7 8 9 10 11 Next ›